Drug Profile
Research programme: proto-oncogene protein c-akt inhibitor - Lyndor Biosciences LLC
Alternative Names: Akt signaling inhibitor 1; AKT-SI1; LD-101Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator H. Lee Moffitt Cancer Center and Research Institute
- Developer Lyndor Biosciences
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
- 16 Mar 2009 Preclinical trials in Cancer in USA (unspecified route)